Brooks Laboratories Limited (BROOKS) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Brooks Laboratories Limited stock ₹26.36, price ₹65.75, that is 59.9% below the price, quality 58 out of 100. Rating: strongly overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range ₹37.11 – ₹194.97 · fair‑value band ₹19.21 – ₹35.11 · the ₹65.75 price screens above the ₹26.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Brooks Laboratories in your weekly email
Every Wednesday you see whether Brooks Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally.
Show moreShow less
The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc.
It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services.
The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and Africa.
Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
Stock analysis
Brooks Laboratories Limited (BROOKS) currently trades at ₹65.75, while our model-based Fair Value estimate is ₹26.36, 60% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹150.29 per share, and 8 of the 23 models we run sit above the ₹65.75 price.
Bear case: the Asset-Based group reads lowest at ₹4.04, and 15 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹19.21 (bear) to ₹35.11 (bull), the price of ₹65.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Brooks Laboratories Limited reported revenue of ₹857M in FY2026 versus ₹912M in FY2022, a compound −1.5%/yr. Reported net income was ₹246M in FY2026.
Key figures
Market cap ₹1.9B (≈ $20.6M) Micro · P/E ratio 14.2 · P/S ratio 2.33 · EPS (TTM) ₹4.63 · Net margin 15.9% · Return on equity 22.3% · Return on assets (EBIT) 1.1% (5-year average) · Operating margin 6.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 63 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 77% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −60%, BROOKS screens richer than that median.
Fair Value models
Bear₹19.21Fair Value ₹26.36Bull₹35.11
Price ₹65.75 · Downside -59.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹2.85 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Start year 2021 (pandemic). Over 10 years: +0.7% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.1% (2021) → 6.4% (2026)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+29.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +24.7% a year for the price.
Compare Brooks Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−59.9% · Bottom 25%
Profitability
Return on equity (12 months)22.3% · Top 25%
Return on assets16.6% · Top 25%
Net margin (12 months)15.9% · Top 25%
Operating margin (12 months)6.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)−10.0% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)14.2× · Cheaper than median
P/B1.58× · Cheaper than median
P/S (12 months)2.33× · Cheaper than median
Price / free cash flow (fiscal year)38.1× · Pricier than median
EV/EBITDA31.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)0· sector 25
PAST (return on equity)89· sector 25
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Brooks Laboratories Limited (BROOKS) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of ₹26.36 versus a price of ₹65.75, about 60% lower (overvalued).
What is the fair value of BROOKS?
Our model-based fair value for Brooks Laboratories Limited is ₹26.36 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹65.75.
What is the quality score of BROOKS?
Brooks Laboratories Limited has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Brooks Laboratories Limited (BROOKS)?
Our model-based price target is the fair value of ₹26.36 (as of Nov 10, 2026) from 23 valuation models. Cautious scenario ₹19.21, optimistic scenario ₹35.11. It is a calculation from audited fundamentals, not an analyst target.
What is the Brooks Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹26.36, about 60% lower versus a price of ₹65.75 (overvalued). Cautious scenario ₹19.21, optimistic scenario ₹35.11. The calculation is refreshed regularly with new filings.
What is the revenue of Brooks Laboratories Limited (BROOKS)?
Brooks Laboratories Limited reported trailing-twelve-month revenue of about ₹832M (latest available figure, as of Nov 10, 2026).
What growth is priced into Brooks Laboratories Limited (BROOKS)?
For today's price to be fair in a discounted-cash-flow model, Brooks Laboratories Limited would have to grow free cash flow by +29.8 % per year for five years (discount rate 12.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.2 % per year. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of BROOKS use?
Our models discount Brooks Laboratories Limited at 12.8 %: a base by market capitalisation (nano), damped by beta 1.15, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Brooks Laboratories Limited that is +29.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.8 %) and the same formula as our fair value.
How much growth has Brooks Laboratories Limited (BROOKS) delivered so far?
Over the past 5 years revenue at Brooks Laboratories Limited grew +2.2 % a year. The price currently implies free-cash-flow growth of +29.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Brooks Laboratories Limited (BROOKS) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Brooks Laboratories Limited (+29.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Brooks Laboratories Limited (BROOKS)?
The free-cash-flow yield on the price is 2.63 %: that much free cash flow Brooks Laboratories Limited produces per unit of market value. When it exceeds the discount rate of our models (12.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Brooks Laboratories Limited (BROOKS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Brooks Laboratories Limited it is ₹26.36 per share (as of Nov 10, 2026), against a price of ₹65.75. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Brooks Laboratories Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, BROOKS trades above its calculated fair value: price ₹65.75, fair value ₹26.36, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BROOKS?
No. The price is what the market pays today (₹65.75); the fair value is what the company's own numbers justify (₹26.36). For Brooks Laboratories Limited the two are ₹39.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Brooks Laboratories Limited worth?
The market values Brooks Laboratories Limited at about ₹1.9B (market capitalisation, as of Nov 10, 2026). Per share that is ₹65.75; our models calculate a fair value of ₹26.36 per share.
What do the bullish and bearish scenarios say about BROOKS?
Our models span a range for Brooks Laboratories Limited: cautious scenario ₹19.21, base ₹26.36, optimistic ₹35.11 per share (as of Nov 10, 2026, price ₹65.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BROOKS?
Brooks Laboratories Limited trades at a price-to-earnings ratio of 14.2 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹26.36 is built from several models across several years. Other multiples: P/B 1.6, P/S 2.3, EV/EBITDA 31.4.
How solid is the balance sheet of Brooks Laboratories Limited (BROOKS)?
Balance-sheet figures for Brooks Laboratories Limited (as of Nov 10, 2026): return on equity 22.3%, debt of 0.01 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is BROOKS from its 52-week high?
Brooks Laboratories Limited trades at ₹65.75, about 40% below its 52-week high of ₹109.82 and 77% above the low of ₹37.11 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹26.36 is for.
Which stocks are comparable to Brooks Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Brooks Laboratories Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹65.75, calculated fair value ₹26.36 (−60%), Quality Score 58/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BROOKS calculated?
We run Brooks Laboratories Limited through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹26.36 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Brooks Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Brooks Laboratories Limited (BROOKS)?
The closing price on Nov 9, 2026 was ₹65.75. Our model-based fair value is ₹26.36, about 60% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Brooks Laboratories Limited right now?
The price sits above even our optimistic bull case (₹35.11). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹19.21 to ₹35.11) leaves room in how you read the outcome.
Key figures of Brooks Laboratories Limited
How large is the market capitalisation of Brooks Laboratories Limited (BROOKS)?
The market capitalisation of Brooks Laboratories Limited is ₹1.9B (≈ $20.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Brooks Laboratories Limited (BROOKS)?
The price-to-sales ratio of Brooks Laboratories Limited is 2.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Brooks Laboratories Limited (BROOKS)?
Earnings per share at Brooks Laboratories Limited are ₹4.63 (price ÷ EPS = P/E 14.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Brooks Laboratories Limited (BROOKS)?
The net margin of Brooks Laboratories Limited is 15.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Brooks Laboratories Limited (BROOKS)?
The return on equity (ROE) of Brooks Laboratories Limited is 22.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Brooks Laboratories Limited (BROOKS)?
On an EBIT basis the return on assets of Brooks Laboratories Limited is 1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Brooks Laboratories Limited (BROOKS)?
The operating margin of Brooks Laboratories Limited is 6.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Brooks Laboratories Limited (BROOKS)?
Revenue at Brooks Laboratories Limited is growing −10.0% versus a year earlier (3y avg +11.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Brooks Laboratories Limited (BROOKS) carry?
The net debt of Brooks Laboratories Limited is ₹9.7M (fiscal year 2026, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Brooks Laboratories Limited in the live analysis
One click puts Brooks Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026